Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040078 | 0.88 | RAB9A (0.47) | KMT2ARAB9ANPC1TDP1TSHR | |
| SCHEMBL6282719 | 0.84 | RAB9A (0.46) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL6288075 | 0.84 | RAB9A (0.46) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL6291026 | 0.84 | RAB9A (0.49) | KMT2ARAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL6285279 | 0.83 | RAB9A (0.45) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL6287981 | 0.82 | RAB9A (0.47) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6287059 | 0.82 | RAB9A (0.43) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6285420 | 0.82 | RAB9A (0.43) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL6287643 | 0.81 | RAB9A (0.54) | KMT2ARAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL7037672 | 0.81 | RAB9A (0.46) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | GAA 4704/4885HTT 3042/4885HSD17B10 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.